Madrigal Pharmaceuticals (MDGL) Upgraded by Zacks Investment Research to Hold

Madrigal Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Madrigal Pharmaceuticals Upgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Madrigal Pharmaceuticals (MDGL) Upgraded by Zacks Investment Research to Hold